Golden Biotechnology Corporation (GoldenBiotech)(4132.TWO), founded in 2002, is a Taiwanese based leading pharmaceutical company which dedicates to discovering new compounds and developing innovative therapeutics against serious and rare diseases in hopes to improve and promote a lasting quality of life, health and longevity for people. GoldenBiotech also develops evidence-based health supplement products. The current focus of GoldenBiotech targets on the development of Antroquinonol®. Antroquinonol® was discovered in 2006 and its compound structure, preparation methods and applicable indications have been protected with patents worldwide. As of today, there are a total of more than 140 patents in over 40 countries/regions. After many years of dedicated development, GoldenBiotech has set up not only PIC/S GMP certified facilities, but also chemical synthesis plant. Now GoldenBiotech has been well prepared for further clinical development as well as future global market demands, welcoming all possible collaborations with open arms. The current pipeline of Antroquinonol® includes clinical developments in COVID-19, non-small cell lung cancer, pancreatic cancer, acute myeloid leukemia, hepatocellular carcinomas, breast cancer, ovarian cancer, Alzheimer’s disease, hypercholesterolemia and hyperlipidemia, atopic dermatitis, and hepatitis.